2010Zhonghua zhongyiyao zazhiRequires access

Effect of Shenmai Injection on cellular immunity of patients with chronic obstructive pulmonary disease at acute exacerbation stage.

Liu HouYing, Mei Wang, Jiangping Li, Luo XinYi, Xiaowei Li

Open publisher page 1 citations

Abstract

Objective: This paper investigates Shenmai Injection’s effect on the cellular immunity of patients with acute exacerbated chronic obstructive pulmonary disease (AECOPD). Methods: 92 cases of AECOPD patients are randomly divided into two groups----control group and treatment group, each with 46 patients. Patients in the two groups are given the same treatment such as anti-inflammatory, astiasthmatic, eliminating phlegm, inhale oxygen. Based on conventional treatment, the treatment group dissolves 40mL of Shenmai Injection in 250mL of injection glucose (5%). Such solution is dripped in vein continuously for two courses of treatment, with ten drops for a course of treatment and once a drop. Indexes of CD+3, CD+4, CD+8of peripheral blood T lymphocyte subsets and ratio of CD+4/CD+8 are tested before two weeks and after two weeks of the treatment, in order to discuss the effect of Shenmai Injection on the cellular immunity of patients with acute exacerbation of chronic obstructive pulmonary disease. Results: After two weeks' treatment, the indexes of CD+3, CD+4 raise up, the indexes of CD+8 go down, and the ratio of CD4+/CD8+ increases. In contrast, there is a significant difference for the patients before the treatment; So is the same with Indexes of CD+3, CD4+, CD8+ and ratio of CD+4/CD+8 to the patients in the treatment group and those in the control group after two weeks. Conclusion: Shenmai Injection can improve the AECOPD patient’s cellular immunity.

About this research paper

What this paper is about

Objective: This paper investigates Shenmai Injection’s effect on the cellular immunity of patients with acute exacerbated chronic obstructive pulmonary disease (AECOPD). Methods: 92 cases of AECOPD patients are randomly divided into two groups----control group and treatment group, each with 46 patients. Patients in the two groups are given the same treatment such as anti-inflammatory, astiasthmatic, eliminating phlegm, inhale oxygen. Based on conventional treatment, the treatment group dissolves 40mL of Shenmai Injection in 250mL of injection glucose (5%). Such solution is dripped in vein continuously for two courses of treatment, with ten drops for a course of treatment and once a drop. Indexes of CD+3, CD+4, CD+8of peripheral blood T lymphocyte subsets and ratio of CD+4/CD+8 are tested before two weeks and after two weeks of the treatment, in order to discuss the effect of Shenmai Injection on the cellular immunity of patients with acute exacerbation of chronic obstructive pulmonary disease. Results: After two weeks' treatment, the indexes of CD+3, CD+4 raise up, the indexes of CD+8 go down, and the ratio of CD4+/CD8+ increases. In contrast, there is a significant difference for the patients before the treatment; So is the same with Indexes of CD+3, CD4+, CD8+ and ratio of CD+4/CD+8 to the patients in the treatment group and those in the control group after two weeks. Conclusion: Shenmai Injection can improve the AECOPD patient’s cellular immunity.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective: This paper investigates Shenmai Injection’s effect on the cellular immunity of patients with acute exacerbated chronic obstructive pulmonary disease (AECOPD). Methods: 92 cases of AECOPD patients are randomly divided into two groups----control group and treatment group, each with 46 patients. Patients in the two groups are given the same treatment such as anti-inflammatory, astiasthmatic, eliminating phlegm, inhale oxygen. Based on conventional treatment, the treatment group dissolves 40mL of Shenmai Injection in 250mL of injection glucose (5%). Such solution is dripped in vein continuously for two courses of treatment, with ten drops for a course of treatment and once a drop. Indexes of CD+3, CD+4, CD+8of peripheral blood T lymphocyte subsets and ratio of CD+4/CD+8 are tested before two weeks and after two weeks of the treatment, in order to discuss the effect of Shenmai Injection on the cellular immunity of patients with acute exacerbation of chronic obstructive pulmonary disease. Results: After two weeks' treatment, the indexes of CD+3, CD+4 raise up, the indexes of CD+8 go down, and the ratio of CD4+/CD8+ increases. In contrast, there is a significant difference for the patients before the treatment; So is the same with Indexes of CD+3, CD4+, CD8+ and ratio of CD+4/CD+8 to the patients in the treatment group and those in the control group after two weeks. Conclusion: Shenmai Injection can improve the AECOPD patient’s cellular immunity.

Key concepts: Medicine, Exacerbation, Immunity, Pulmonary disease, CD8, Acute exacerbation of chronic obstructive pulmonary disease, Cellular immunity, Gastroenterology

Related papers

Back to paper searchBrowse research topicsOriginal source
Effect of Shenmai Injection on cellular immunity of patients with chronic obstructive pulmonary disease at acute exacerbation stage. — Research Paper | ScholarLens